S. Misale

发表

Anatomic position determines oncogenic specificity in melanoma

Joshua M. Weiss, R. White, B. Taylor, 2020, Nature.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Enzo Medico, Roberta Schiavo, F. Nicolantonio, 2012, Nature.

Targeting the CBM complex causes Treg cells to prime tumors for immune checkpoint therapy

A. Villani, B. Medoff, M. Ligorio, 2019, Nature.

KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy

I. Nagtegaal, F. Nicolantonio, A. Bardelli, 2013, International journal of cancer.

HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers.

David R. Jones, M. Berger, C. Rudin, 2020, Cancer discovery.

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer

R. Bosotti, A. Isacchi, A. Bardelli, 2015, Journal of the National Cancer Institute.

Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer

Martin J. Aryee, Linda T. Nieman, M. Lawrence, 2019, Cell.

Running title : STAT 3 contributes to cell transformation

V. Poli, J. Campisi, P. Pinton, 2022 .

Title: HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers Running title: Antitumoral activity of anti-HER2 ADCs in lung cancer

Anuja, David C. Jones, M. Berger, 2020 .

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants

N. Kraut, S. Misale, M. Petronczki, 2022, Cancer discovery.

Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer

Jian Yu, A. Bardelli, Lin Zhang, 2018, Oncogene.

STAT3 can serve as a hit in the process of malignant transformation of primary cells

V. Poli, J. Campisi, P. Pinton, 2012, Cell Death and Differentiation.

Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

Amanda R. Kulick, M. Ladanyi, M. Berger, 2019, Nature Medicine.

Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.

Gang Li, R. Shoemaker, Shunqi Yan, 2015, Cancer discovery.

Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers

M. Nowak, I. Bozic, A. Bardelli, 2015, Nature Communications.

Targeting the CBM complex causes Treg cells to prime tumors for immune checkpoint therapy

A. Villani, B. Medoff, M. Ligorio, 2019, Nature.

Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.

A. Bardelli, F. Di Nicolantonio, S. Misale, 2014, Cancer discovery.

KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

David R. Jones, S. Sihag, A. Drilon, 2021, Clinical Cancer Research.

EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer.

N. Rosen, A. Bardelli, Y. Murciano-Goroff, 2020, Cancer discovery.

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

A. Bardelli, M. Buscarino, F. Di Nicolantonio, 2014, Science Translational Medicine.

Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

M. Salido, A. Bardelli, J. Albanell, 2015, Clinical Cancer Research.

TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells

A. Bardelli, F. Di Nicolantonio, S. Hobor, 2014, Clinical Cancer Research.

Molecular characterization of acquired resistance to KRAS G12C inhibition in gastrointestinal cancers

N. Socci, S. Lowe, J. Reis-Filho, 2022 .

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

P. Zarrinkar, Patricia Greninger, C. Benes, 2018, Clinical Cancer Research.

resistance to EGFR blockade in colorectal cancer cells

F. Nicolantonio, A. Bardelli, S. Hobor, 2014 .

Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of

S. Misale, 2014 .

MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

A. Bardelli, L. Trusolino, A. Bertotti, 2016, Science Translational Medicine.

Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

N. Socci, M. Berger, S. Lowe, 2022, Cancer discovery.

Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation

Amanda R. Kulick, M. Ladanyi, M. Berger, 2019, Nature Network Boston.

Resistance is futile with fourth-generation EGFR inhibitors

S. Misale, M. Marasco, 2022, Nature Cancer.

Abstract A173: Potent anti-tumor activity of entrectinib in patient-derived models harboring oncogenic gene rearrangements of NTRKs

R. Shoemaker, A. Bardelli, Kyoung-Mee Kim, 2015 .

TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors.

B. Taylor, M. Berger, A. Drilon, 2020, Cancer discovery.

Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers.

Ilinca Ş. Aricescu, R. Yaeger, E. de Stanchina, 2023, The oncologist.

Targeting the CBM complex causes Treg cells to prime tumors for immune checkpoint therapy

A. Villani, B. Medoff, M. Ligorio, 2019 .

Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer

A. Bardelli, M. Buscarino, F. Di Nicolantonio, 2014, Science Translational Medicine.

P2.08 Emergence of Kras Mutations and Acquired Resistance to Anti Egfr Therapy in Colorectal Cancer

F. Nicolantonio, A. Bardelli, M. Janakiraman, 2012 .

Abstract C94: Heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer are sensitive to concomitant inhibition of EGFR and MEK.

F. Nicolantonio, A. Bardelli, M. Buscarino, 2013 .

KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy

I. Nagtegaal, F. Nicolantonio, A. Bardelli, 2013, International journal of cancer.